

IN THE CLAIMS:

Please amend Claims 1, 12 and 33 as shown.

a¹ 1. (Amended) Folliculo stellate-derived growth factor in isolated substantially pure form as compared to the naturally occurring growth factor.

Please cancel Claims 6-11, 26 to 32 and 37 without prejudice or disclaimer.

a² ¹²26. (Amended) A method for producing a substantially pure folliculo stellate-derived growth factor (FSdGF) in isolated form as compared to the naturally occurring growth factor, which method comprises:

- (a) providing a biological sample containing levels of FSdGF;
- (b) extracting the solubilized portion of the sample;
- (c) partially purifying the FSdGF from the extract using an aqueous salt-precipitation step;
- (d) fractionating the purified extract using affinity chromatograph employing heparin moieties linked to an insoluble support as the stationary phase and employing a salt gradient mobile phase of increasing salt concentration;
- (e) fractionating the extract using gel exclusion chromatography;
- (f) fractionating the sample using liquid chromatography; and
- (g) purifying the extract using reverse-phase high pressure liquid chromatography.

a³ 33. (Amended) A method of obtaining a substantially pure folliculo stellate-derived growth factor (FSdGF) in isolated form

as compared to the naturally occurring factor, which method comprises:

- 3
a
cont
- (a) providing a biological sample containing levels of FSdGF;
 - (b) extracting the solubilized portion of the sample;
 - (c) partially purifying the FSdGF from the extract using an aqueous salt-precipitation step;
 - (d) fractionating the purified extract using affinity chromatography employing heparin moieties linked to an insoluble support as the stationary phase and employing a salt gradient mobile phase of increasing salt concentration;
 - (e) fractionating the extract using gel exclusion chromatography;
 - (f) purifying the extract using reverse-phase high pressure liquid chromatography.

Claim 35, line 2, delete "35", and insert --34--.

REMARKS

Applicant has amended independent Claims 1, 26 and 33. The added description is to more clearly explain and define the present invention. Applicant has obtained a purified growth factor which has a number of uses including increasing the rate of wound healing and increasing the rate of growth of vascular cells in mammals.

The attention of Examiner S. Guest is directed to additional related applications U.S.S.N. 360,229 and 360,235, both filed June 1, 1989.

RESTRICTION PURSUANT TO 35 U.S.C. 121

The Examiner has required an election of inventions.

Applicant's undersigned attorney on April 25, 1990 provisionally elected with traverse Group I, Claims 12-25, 33-36 and 38-40.